stockrowLeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- −14.3%
- Free cash flow
- −25.8%
- Total debt
- +0.53%
Quarter to September 2026, against a year earlier
Follow LMAT
Alert me
LeMaitre Vascular, Inc. (LMAT) Total debt
LeMaitre Vascular, Inc.'s total debt at the end of fiscal 2025 was $168.6M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $169.3M. Over the past ten years it has ranged from $14.1M (fiscal 2021) to $168.6M (fiscal 2025) — the current reading is the highest in ten years. LeMaitre Vascular, Inc. ranks 21st of 50 Medical Instruments & Supplies companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $168.6M | 0.52% |
| FY2024 | $167.8M | 1,040.53% |
| FY2022 | $14.7M | 4.57% |
| FY2021 | $14.1M | (63.01%) |
| FY2020 | $38.0M | 142.06% |
| FY2019 | $15.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $169.3M | 0.13% |
| Jun 2026 | $169.1M | 0.13% |
| Mar 2026 | $168.9M | 0.13% |
| Dec 2025 | $168.6M | 0.13% |
| 20 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | $2.0B |
| STVN Stevanato Group S.p.A. compare | $545.0M |
| WRBY Warby Parker Inc. compare | $170.2M |
| LMAT LeMaitre Vascular, Inc. | $169.3M |
| KMTS Kestra Medical Technologies, Ltd. compare | $72.5M |
| AZTA Azenta, Inc. compare | $72.0M |
| ATRC AtriCure, Inc. compare | $61.0M |
| STAA STAAR Surgical Company compare | $31.2M |
| PLSE Pulse Biosciences, Inc compare | $9.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on LMAT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement